Transfusion Medicine Reviews
Volume 20, Issue 4 , Pages 283-293 , October 2006

Clinical Approaches Involving Thrombopoietin to Shorten the Period of Thrombocytopenia After High-Dose Chemotherapy

References 

  1. Kaushansky K, Broudy VC, Lin N, et al. Thrombopoietin, the Mpl ligand, is essential for full megakaryocyte development. Proc. Natl. Acad. Sci. U. S. A. 1995;92:3234–3238
  2. Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood. 2002;100:3457–3469
  3. Souyri M, Vigon I, Penciolelli JF, et al. A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors. Cell. 1990;63:1137–1147
  4. Vigon I, Mornon JP, Cocault L, et al. Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: Identification of a member of the hematopoietic growth factor receptor superfamily. Proc. Natl. Acad. Sci. U. S. A. 1992;89:5640–5644
  5. Wendling F, Maraskovsky E, Debili N, et al. cMpl ligand is a humoral regulator of megakaryocytopoiesis. Nature. 1994;369:571–574
  6. Gordon MS, Hoffman R. Growth factors affecting human thrombocytopoiesis: Potential agents for the treatment of thrombocytopenia. Blood. 1992;80:302–307
  7. Gainsford T, Roberts AW, Kimura S, et al. Cytokine production and function in c-mpl–deficient mice: No physiologic role for interleukin-3 in residual megakaryocyte and platelet production. Blood. 1998;91:2745–2752
  8. Gainsford T, Nandurkar H, Metcalf D, et al. The residual megakaryocyte and platelet production in c-mpl–deficient mice is not dependent on the actions of interleukin-6, interleukin-11, or leukemia inhibitory factor. Blood. 2000;95:528–534
  9. Avecilla ST, Hattori K, Heissig B, et al. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat. Med. 2004;10:64–71
  10. Moore KA. Recent advances in defining the hematopoietic stem cell niche. Curr. Opin. Hematol. 2004;11:107–111
  11. Muller-Sieburg CE, Deryugina E. The stromal cells' guide to the stem cell universe. Stem Cells. 1995;13:477–486
  12. Nilsson SK, Johnston HM, Coverdale JA. Spatial localization of transplanted hemopoietic stem cells: Inferences for the localization of stem cell niches. Blood. 2001;97:2293–2299
  13. Yoshimoto M, Shinohara T, Heike T, et al. Direct visualization of transplanted hematopoietic cell reconstitution in intact mouse organs indicates the presence of a niche. Exp. Hematol. 2003;31:733–740
  14. Majka M, Janowska-Wieczorek A, Ratajczak J, et al. Stromal-derived factor 1 and thrombopoietin regulate distinct aspects of human megakaryopoiesis. Blood. 2000;96:4142–4151
  15. Riviere C, Subra F, Cohen-Solal K, et al. Phenotypic and functional evidence for the expression of CXCR4 receptor during megakaryocytopoiesis. Blood. 1999;93:1511–1523
  16. Wang JF, Liu ZY, Groopman JE. The alpha-chemokine receptor CXCR4 is expressed on the megakaryocytic lineage from progenitor to platelets and modulates migration and adhesion. Blood. 1998;92:756–764
  17. Berthebaud M, Riviere C, Jarrier P, et al. RGS16 is a negative regulator of SDF-1-CXCR4 signaling in megakaryocytes. Blood. 2005;106:2962–2968
  18. Rafii S, Shapiro F, Pettengell R, et al. Human bone marrow microvascular endothelial cells support long-term proliferation and differentiation of myeloid and megakaryocytic progenitors. Blood. 1995;86:3353–3363
  19. Avraham H, Scadden DT, Chi S, et al. Interaction of human bone marrow fibroblasts with megakaryocytes: Role of the c-kit ligand. Blood. 1992;80:1679–1684
  20. Zweegman S, Veenhof MA, Debili N, et al. Megakaryocytic differentiation of human progenitor cells is negatively influenced by direct contact with stroma. Leukemia. 1999;13:935–943
  21. Delehanty LL, Mogass M, Gonias SL, et al. Stromal inhibition of megakaryocytic differentiation is associated with blockade of sustained Rap1 activation. Blood. 2003;101:1744–1751
  22. Wilson A, Trumpp A. Bone-marrow haematopoietic-stem-cell niches. Nat. Rev. Immunol. 2006;6:93–106
  23. Raslova H, Roy L, Vourc'h C, et al. Megakaryocyte polyploidization is associated with a functional gene amplification. Blood. 2003;101:541–544
  24. Mattia G, Vulcano F, Milazzo L, et al. Different ploidy levels of megakaryocytes generated from peripheral or cord blood CD34+ cells are correlated with different levels of platelet release. Blood. 2002;99:888–897
  25. Italiano JE, Lecine P, Shivdasani RA, et al. Blood platelets are assembled principally at the ends of proplatelet processes produced by differentiated megakaryocytes. J. Cell. Biol. 1999;147:1299–1312
  26. Choi ES, Nichol JL, Hokom MM, et al. Platelets generated in vitro from proplatelet-displaying human megakaryocytes are functional. Blood. 1995;85:402–413
  27. Patel SR, Hartwig JH, Italiano JE. The biogenesis of platelets from megakaryocyte proplatelets. J. Clin. Invest. 2005;115:3348–3354
  28. Clarke MC, Savill J, Jones DB, et al. Compartmentalized megakaryocyte death generates functional platelets committed to caspase-independent death. J. Cell. Biol. 2003;160:577–587
  29. De Botton S, Sabri S, Daugas E, et al. Platelet formation is the consequence of caspase activation within megakaryocytes. Blood. 2002;100:1310–1317
  30. Ito T, Ishida Y, Kashiwagi R, et al. Recombinant human c-Mpl ligand is not a direct stimulator of proplatelet formation in mature human megakaryocytes. Br. J. Haematol. 1996;94:387–390
  31. Choi ES, Hokom MM, Chen JL, et al. The role of megakaryocyte growth and development factor in terminal stages of thrombopoiesis. Br. J. Haematol. 1996;95:227–233
  32. Kopp HG, Avecilla ST, Hooper AT, et al. The bone marrow vascular niche: home of HSC differentiation and mobilization. Physiology. 2005;20:349–356
  33. Hamada T, Mohle R, Hesselgesser J, et al. Transendothelial migration of megakaryocytes in response to stromal cell-derived factor 1 (SDF-1) enhances platelet formation. J. Exp. Med. 1998;188:539–548
  34. Avraham H, Cowley S, Chi SY, et al. Characterization of adhesive interactions between human endothelial cells and megakaryocytes. J. Clin. Invest. 1993;91:2378–2384
  35. Hoffman R. Regulation of megakaryocytopoiesis. Blood. 1989;74:1196–1212
  36. Italiano JE, Shivdasani RA. Megakaryocytes and beyond: The birth of platelets. J. Thromb. Haemost. 2003;1:1174–1182
  37. Kuter DJ, Goodnough LT, Romo J, et al. Thrombopoietin therapy increases platelet yields in healthy platelet donors. Blood. 2001;98:1339–1345
  38. Harker LA, Roskos LK, Marzec UM, et al. Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers. Blood. 2000;95:2514–2522
  39. O'Malley CJ, Rasko JE, Basser RL, et al. Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation. Blood. 1996;88:3288–3298
  40. Basser RL, Rasko JE, Clarke K, et al. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood. 1997;89:3118–3128
  41. Rasko JE, Basser RL, Boyd J, et al. Multilineage mobilization of peripheral blood progenitor cells in humans following administration of PEG-rHuMGDF. Br. J. Haematol. 1997;97:871–880
  42. Bussel JB, George JN, Kuter DJ, et al. An open-label, dose-finding study evaluating the safety and platelet response of a novel thrombopoietic protein (AMG 531) in thrombocytopenic adult patients with immune thrombocytopenic purpura (ITP). Blood. 2003;102:86
  43. Erickson-Miller CL, Delorme E, Tian SS, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp. Hematol. 2005;33:85–93
  44. Inagaki K, Oda T, Naka Y, et al. Induction of megakaryocytopoiesis and thrombocytopoiesis by JTZ-132, a novel small molecule with thrombopoietin mimetic activities. Blood. 2004;104:58–64
  45. Dercksen MW, Rodenhuis S, Dirkson MK, et al. Subsets of CD34+ cells and rapid hematopoietic recovery after peripheral-blood stem-cell transplantation. J. Clin. Oncol. 1995;13:1922–1932
  46. Feng R, Shimazaki C, Inaba T, et al. CD34+/CD41a+ cells best predict platelet recovery after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 1998;21:1217–1222
  47. Weaver CH, Potz J, Redmond J, et al. Engraftment and outcomes of patients receiving myeloablative therapy followed by autologous peripheral blood stem cells with a low CD34+ cell content. Bone Marrow Transplant. 1997;19:1103–1110
  48. Shpall EJ, Champlin R, Glaspy JA. Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. Biol. Blood Marrow Transplant. 1998;4:84–92
  49. Engel C, Loeffler M, Franke H, et al. Endogenous thrombopoietin serum levels during multicycle chemotherapy. Br. J. Haematol. 1999;105:832–838
  50. Takeyama K, Ohto H. PBSC mobilization. Transfus. Apher. Sci. 2004;31:233–243
  51. Filshie RJ. Cytokines in haemopoietic progenitor mobilisation for peripheral blood stem cell transplantation. Curr. Pharm. Des. 2002;8:379–394
  52. Honda K, Takenaka K, Shinagawa K, et al. Synergistic effects of pegylated recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor on mobilization of hematopoietic progenitor and stem cells with long-term repopulating ability into peripheral blood in mice. Bone Marrow Transplant. 2001;28:329–334
  53. Gajewski JL, Rondon G, Donato ML, et al. Use of thrombopoietin in combination with chemotherapy and granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization. Biol. Blood Marrow Transplant. 2002;8:550–556
  54. Linker C, Anderlini P, Herzig R, et al. Recombinant human thrombopoietin augments mobilization of peripheral blood progenitor cells for autologous transplantation. Biol. Blood Marrow Transplant. 2003;9:405–413
  55. Somlo G, Sniecinski I, ter Veer A, et al. Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy. Blood. 1999;93:2798–2806
  56. Torii Y, Nitta Y, Akahori H, et al. Mobilization of primitive haemopoietic progenitor cells and stem cells with long-term repopulating ability into peripheral blood in mice by pegylated recombinant human megakaryocyte growth and development factor. Br. J. Haematol. 1998;103:1172–1180
  57. Roberts AW, Foote S, Alexander WS, et al. Genetic influences determining progenitor cell mobilization and leukocytosis induced by granulocyte colony-stimulating factor. Blood. 1997;89:2736–2744
  58. Kirito K, Fox N, Kaushansky K. Thrombopoietin stimulates Hoxb4 expression: an explanation for the favorable effects of TPO on hematopoietic stem cells. Blood. 2003;102:3172–3178
  59. Wendling F. Thrombopoietin: Its role from early hematopoiesis to platelet production. Haematologica. 1999;84:158–166
  60. Borge OJ, Ramsfjell V, Veiby OP, et al. Thrombopoietin, but not erythropoietin promotes viability and inhibits apoptosis of multipotent murine hematopoietic progenitor cells in vitro. Blood. 1996;88:2859–2870
  61. Vadhan-Raj S, Patel S, Bueso-Ramos C, et al. Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia. J. Clin. Oncol. 2003;21:3158–3167
  62. Bertolini F, Battaglia M, Pedrazzoli P, et al. Megakaryocytic progenitors can be generated ex vivo and safely administered to autologous peripheral blood progenitor cell transplant recipients. Blood. 1997;89:2679–2688
  63. Prince HM, Simmons PJ, Whitty G, et al. Improved haematopoietic recovery following transplantation with ex vivo–expanded mobilized blood cells. Br. J. Haematol. 2004;126:536–545
  64. Decaudin D, Vantelon JM, Bourhis JH, et al. Ex vivo expansion of megakaryocyte precursor cells in autologous stem cell transplantation for relapsed malignant lymphoma. Bone Marrow Transplant. 2004;34:1089–1093
  65. Scheding S, Bergmannn M, Rathke G, et al. Additional transplantation of ex vivo generated megakaryocytic cells after high-dose chemotherapy. Haematologica. 2004;89:630–631
  66. Ratajczak MZ, Ratajczak J, Machalinski B, et al. In vitro and in vivo evidence that ex vivo cytokine priming of donor marrow cells may ameliorate posttransplant thrombocytopenia. Blood. 1998;91:353–359
  67. Bruno S, Gunetti M, Gammaitoni L, et al. In vitro and in vivo megakaryocyte differentiation of fresh and ex-vivo expanded cord blood cells: Rapid and transient megakaryocyte reconstitution. Haematologica. 2003;88:379–387
  68. Feng Y, Zhang L, Xiao ZJ, et al. An effective and simple expansion system for megakaryocyte progenitor cells using a combination of heparin with thrombopoietin and interleukin-11. Exp. Hematol. 2005;33:1537–1543
  69. Bruno S, Gunetti M, Gammaitoni L, et al. Fast but durable megakaryocyte repopulation and platelet production in NOD/SCID mice transplanted with ex-vivo expanded human cord blood CD34+ cells. Stem Cells. 2004;22:135–143
  70. Perez LE, Rinder HM, Wang C, et al. Xenotransplantation of immunodeficient mice with mobilized human blood CD34+ cells provides an in vivo model for human megakaryocytopoiesis and platelet production. Blood. 2001;97:1635–1643
  71. van den Oudenrijn S, von dem Borne AE, de Haas M. Differences in megakaryocyte expansion potential between CD34(+) stem cells derived from cord blood, peripheral blood, and bone marrow from adults and children. Exp. Hematol. 2000;28:1054–1061
  72. Abrahamsen JF, Bakken AM, Bruserud O. Cryopreserving human peripheral blood progenitor cells with 5-percent rather than 10-percent DMSO results in less apoptosis and necrosis in CD34+ cells. Transfusion. 2002;42:1573–1580
  73. Abrahamsen JF, Bakken AM, Bruserud O, et al. Flow cytometric measurement of apoptosis and necrosis in cryopreserved PBPC concentrates from patients with malignant diseases. Bone Marrow Transplant. 2002;29:165–171
  74. Abrahamsen JF, Rusten L, Bakken AM, et al. Better preservation of early hematopoietic progenitor cells when human peripheral blood progenitor cells are cryopreserved with 5 percent dimethylsulfoxide instead of 10 percent dimethylsulfoxide. Transfusion. 2004;44:785–789
  75. Vadhan-Raj S, Kavanagh JJ, Freedman RS, et al. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study. Lancet. 2002;359:2145–2152
  76. Kopp HG, Avecilla ST, Hooper AT, et al. Tie2 activation contributes to hemangiogenic regeneration after myelosuppression. Blood. 2005;106:505–513

PII: S0887-7963(06)00031-9

doi: 10.1016/j.tmrv.2006.05.003

Transfusion Medicine Reviews
Volume 20, Issue 4 , Pages 283-293 , October 2006

Article Tools

* Image Usage & Resolution